93 articles by PIAI team.
This practical guide explains the UFLPA Entity List and its impact on US importers. Follow our step-by-step framework for UFLPA compliance to avoid costly shipment detentions, protect your brand, and build a resilient supply chain.
US pharma faces growing risks from Chinese API dependency. This guide explains why traditional methods fail and outlines a proactive framework for China API export monitoring across regulatory, political, and market signals to protect your supply chain.
Understand the EU's Spitzenkandidaten process, the controversial system for electing the European Commission President. This guide explains how it works, its history, and why it's a critical early indicator of future EU regulatory and policy shifts for any business or organization.
Discover how German state elections reshape federal energy and climate policy through the powerful Bundesrat. Learn why tracking these regional votes is key to anticipating regulatory risk and gaining a strategic advantage.
The rise of GLP-1s has fractured the patient advocacy landscape, creating new risks and opportunities for pharma. This case study analyzes the key advocacy archetypes shaping GLP-1 access policy and explains why dynamic, AI-driven intelligence is now essential.
Internal echo chambers create strategic blind spots that can derail even the most well-planned advocacy strategy. Learn why external validation is critical for success and how an external intelligence platform provides the continuous reality check needed to stay aligned, mitigate risks, and seize opportunities.
Introduction The Post-Brexit Regulatory Divide for Chemicals For any company in the chemical sector, REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) has been a cornerstone of European market access for years. However, since the UK’s departure from the European Union, this single regulatory framework has fractured. Businesses selling chemicals in both Great Britain (England, […]
The EU-Mercosur trade deal is no longer just about tariffs. New EU regulations like EUDR and CSDDD create major compliance hurdles related to deforestation and human rights, demanding a shift from reactive monitoring to proactive, AI-driven signal intelligence.
Discover why traditional stakeholder matrix mapping is a dangerously outdated tool for navigating the complex world of EU pharmaceutical policy. Learn how its static nature creates blind spots and why a shift to dynamic, AI-powered stakeholder intelligence is essential for success.
This guide explains Germany's Supply Chain Act (LkSG) and the EU's Corporate Sustainability Due Diligence Directive (CSDDD). Learn who these laws apply to, what they require, and how they differ to ensure your business remains compliant.